Clinical Trial

Vasoactive Drugs in Intensive Care Unit

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2014-04-16; most recent amendment 2026-01-12.
Status change: Not Yet Recruiting → Recruiting 2014-05-27
Trial Details
NCT Number NCT02118467
Lead Sponsor University of Chicago
Conditions Shock
Enrollment 836 participants
Start Date 2014-05-15
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-13